Page 142 - 2019_11 Resto del Mondo-web

R. Bruna et al.
Standard chemotherapy with interferon
compared with CHOP followed by high- dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA) Blood. 2006;108(8):2540–2544.
8. Brown JR, Feng Y, Gribben JG, et al. Long- term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant. 2007;13(9):1057-1065.
9. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R- HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood. 2008;111(8):4004-4013.
10. Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free sur- vival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2006;24(10):1582-1589.
11. Schulz H, Bohlius JF, Trelle S, et al: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706-714.
12. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative sur- vival in follicular grade 1-2 lymphoma dur- ing 4 decades: the Stanford University expe- rience. Blood. 2013;122(6):981-987.
13. Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Kruczek K, Smith SM, Evens AM. The impact of race, age, and sex in follicular lym- phoma: a comprehensive SEER analysis across consecutive treatment eras. Am J Hematol. 2014;89(6):633-638.
14. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lym- phoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361-1392.
15. López-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for aggressive lymphomas to patients with low- grade lymphoma. J Clin Oncol. 1994;12(7): 1343-1348.
16. Federico M, Vitolo U, Zinzani PL, et al. Prognosis of follicular lymphoma: a pre- dictive model based on a retrospective analy- sis of 987 cases Blood. 2000;95(3):783-789.
17. Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreat- ed patients with follicular lymphoma. Blood. 2002;99(3):856-862.
18. Tarella C, Caracciolo D, Corradini P, et al. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia. 2000;14(4):740-747.
19. Ladetto M, Corradini P, Vallet S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high- dose sequential chemotherapy and auto- grafting at diagnosis: a multicenter, prospec- tive study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002;100(5):1559-1565.
20. Cheson BD, Horning SJ, Coiffier B, et al.
Report of an international workshop to stan- dardize re-sponse criteria for non-Hodgkin’s lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244-1253.
21. Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non- Hodgkin’s lymphomas treated with high- dose chemotherapy and peripheral blood progenitor cell autografting. Blood. 1997;89(2):724-731.
22. Kaplan EL, Meier P. Non parametric estima- tion from incomplete observations. J Am Stat Assoc. 1958;53(282):457-481.
23. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-86.
24. Mantel H, Haenszel W. Statistical aspects of the analysis of data from retrospective stud- ies of disease. J Natl Cancer Inst. 1959; 22(4):719-748.
25. Cox DR. Regression models and life tables. J Royal Stat Soc Series B. 1972;34:187-220.
26. Gray RS. A class of K-sample tests for com- paring the cumulative incidence of a com- peting risk. Ann Stat. 1988;16(3):1141-1154.
27. R Foundation for Statistical Computing, Vienna-A, http://www.R-project.org
28. Solal-Celigny, P. Roy, P. Colombat, et al. Follicular lymphoma international prognos- tic index. Blood. 2004;104(5):1258-1265.
29. Luminari S, Ferrari A, Manni M, et al. Long- term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced- stage symptomatic follicular lymphoma. J Clin Oncol. 2017;36(7):689-696.
30. Shadman M, Li H, Rimsza L, et al. continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-Tositumomab: long-term follow-up of Phase III randomized study SWOG-S0016. J Clin Oncol. 2018;36(7):697- 703.
31. Sarkozy C, Maurer MJ, Link BK, et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analy- sis of French and US cohorts. J Clin Oncol. 2019;37(2):144-152.
32. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, ran- domised controlled trial. Lancet. 2011;377 (9759):42-51.
33. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with in- dolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-1210.
34. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017;377(14):1331-1344.
35. Tarella C, Passera R, Magni M, et al. Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in 1,347 Patients With Lymphoma. J Clin Oncol. 2011,29(7):814-824.
36. Jiménez-Ubieto A, Grande C, Caballero D,
et al., on behalf of GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) Cooperative Study Group. Secondary malignancies and survival out- comes after autologous stem cell transplan- tation for follicular lymphoma in the pre-rit- uximab and rituximab eras: a long-term fol- low-up analysis from the Spanish GELTA- MO registry. Bone Marrow Transplant. 2018;53(6):780-783.
37. Smith SM, Pitcher BN, Jung SH, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: The Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4(4):e176- e182.
38. Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone ver- sus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33(31):3635-3640.
39. Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non- Hodgkin lymphoma. J Clin Oncol. 2017; 35(8):826-833.
40. Tarella C, Gueli A, Delaini F, et al. Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin's Lymphoma: Correlation with Long-Term Survival. PLoS One. 2014; 9(9):e106745.
41. Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after ritux- imab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-2522.
42. Shi Q, Flowers CR, Hiddemann W, et al. Thirty-month completer esponse as a surro- gate end point in first-line follicular lym- phoma Therapy: an individual patient-level analysis of multiple randomized trials. J Clin Oncol. 2017;35(5):552-560.
43. Sorigue M, Mercadal S, Alonso S, et al. Refractoriness to immunochemotherapy in follicular lymphoma: predictive factors and outcome. Hematol Oncol. 2017;35(4):520- 527
44. Provencio M, Royuela A, Torrente M, et al, on behalf of the Spanish Lymphoma Oncology Group. Prognostic value of event- free survival at 12 and 24 months and long- term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group. Cancer. 2017;123(19):3709-3716.
45. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med. 1991;325(22):1525-1533.
46. Ladetto M, Lobetti-Bodoni C, Mantoan B, et al, onbehalf of Fondazione Italiana Linfomi. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-inten- sive program. Blood. 2013;122(23):3759- 3766.
47. Gritti G, Pavoni C, Rambaldi A. Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era? Mediterr J Hematol Infect Dis. 2017;9(1):e2017010.
48. Casulo C, Nastoupil L, Fowler NH, Friedberg JW, Flowers CR. Unmet needs in the first-line treatment of follicular lym- phoma. Ann Oncol. 2017;28(9):2094-2106.
2248
haematologica | 2019; 104(11)